Crescendo Biologics Ltd - Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda
(World News Science)

Crescendo Biologics Ltd (Crescendo), the developer of targeted T-cell engagers, today announced that it has achieved another technical milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE:4502). Crescendo`s global, strategic, multi-target collaboration and license agreement with Takeda was announced in October 2016. Under this agreement, Crescendo`s proprietary transgenic platform and engineering expertise is used to identify and configure Humabody®-based therapeutics against certain targets selected by Takeda. This milestone, for an undisclosed amount, marks the successful delivery of...